摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5α-hydroxy-6β-(4-aminobutylamino)-cholest-7-en-3β-ol | 1191043-92-1

中文名称
——
中文别名
——
英文名称
5α-hydroxy-6β-(4-aminobutylamino)-cholest-7-en-3β-ol
英文别名
5α-hydroxy-6β-(4-aminobutylamino)cholest-7-en-3β-ol;5alpha-Hydroxy-6beta-(4-aminobutylamino)-cholest-7-en-3beta-ol;(3S,5R,6R,9S,10R,13R,14R,17R)-6-(4-aminobutylamino)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,3,4,6,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-3,5-diol
5α-hydroxy-6β-(4-aminobutylamino)-cholest-7-en-3β-ol化学式
CAS
1191043-92-1
化学式
C31H56N2O2
mdl
——
分子量
488.798
InChiKey
LWUBVHHUZJIZGV-FJSNHDTHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.1
  • 重原子数:
    35
  • 可旋转键数:
    10
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.94
  • 拓扑面积:
    78.5
  • 氢给体数:
    4
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    5α,6α-epoxycholest-7-en-3β-ol四亚甲基二胺正丁醇 为溶剂, 反应 40.0h, 以64%的产率得到5α-hydroxy-6β-(4-aminobutylamino)-cholest-7-en-3β-ol
    参考文献:
    名称:
    [EN] PROCESS FOR THE PREPARATION OF STEROL DERIVATIVES
    [FR] PROCÉDÉ POUR LA PRÉPARATION DE DÉRIVÉS DE STÉROL
    摘要:
    本发明涉及一种用于制备甾醇衍生物的方法,包括在含有3至5个碳原子的醇溶剂中,将α-环氧化合物与胺反应的过程。
    公开号:
    WO2013076257A1
点击查看最新优质反应信息

文献信息

  • PROCESS FOR THE PREPARATION OF STEROL DERIVATIVES
    申请人:INSERM (Institut National de la Sante et de la Recherche Medicale)
    公开号:US20140309417A1
    公开(公告)日:2014-10-16
    The present invention relates to a process for the preparation of sterol derivatives comprising the reaction of an α-epoxy compound with an amine in an alcohol comprising 3 to 5 carbon atoms as a solvent.
    本发明涉及一种制备甾醇衍生物的方法,包括在一种含有3至5个碳原子的醇作为溶剂的情况下,将α-环氧化合物与胺反应。
  • Process for the preparation of sterol derivatives
    申请人:INSERM (Institut National de la Sante et de la Recherche Medicale)
    公开号:US09447141B2
    公开(公告)日:2016-09-20
    The present invention relates to a process for the preparation of sterol derivatives comprising the reaction of an α-epoxy compound with an amine in an alcohol comprising 3 to 5 carbon atoms as a solvent.
    本发明涉及一种制备甾醇衍生物的方法,其中将α-环氧化合物与一种胺在含有3到5个碳原子的醇类溶剂中进行反应。
  • Synthesis of New Alkylaminooxysterols with Potent Cell Differentiating Activities: Identification of Leads for the Treatment of Cancer and Neurodegenerative Diseases
    作者:Philippe de Medina、Michael R. Paillasse、Bruno Payré、Sandrine Silvente-Poirot、Marc Poirot
    DOI:10.1021/jm901063e
    日期:2009.12.10
    We describe here the syntheses and the biological properties of new alkylaminooxysterols. Compounds were synthesized through the trans-diaxial aminolysis of 5,6-alpha-epoxysterols with various natural amines including histamine, putrescine, spermidine, or spermine. The regioselective synthesis of these 16 new 5 alpha-hydroxyl-6 beta-aminoalkylsterols is presented. Compounds were first screened for dendrite outgrowth and cytotoxicity in vitro, and two leads were selected and further characterized. 5 alpha-Hydroxy-6 beta-[2-(1-H-imidazol-4-yl)ethylamino]cholestan -3 beta-ol, called dendrogenin A, induced growth control, differentiation, and the death of tumor cell lines representative of various cancers including metastatic melanoma and breast cancer. 5 alpha-hydroxyl-6 beta-[3-(4-aminobutylamino)propylamino]cholest-7-en-3 beta-ol, called dendrogenin B, induced neurite outgrowth on various cell lines, neuronal differentiation in pluripotent cells, and survival of normal neurones at nanomolar concentrations. In summary, we report that two new alkylaminooxysterols, dendrogenin A and dendrogenin B, are the first members of a class of compounds that induce cell differentiation at nanomolar concentrations and represent promising new leads for the treatment of cancer or neurodegenerative diseases.
  • METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS
    申请人:The Rockefeller University
    公开号:EP3402477A2
    公开(公告)日:2018-11-21
  • TREATMENT AND DIAGNOSIS OF CANCER
    申请人:Rgenix, Inc.
    公开号:US20190125745A1
    公开(公告)日:2019-05-02
    This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors for the treatment of cancer.
查看更多